Eli Lilly and Company has fallen a further 6.7% this week to $1,152.54, yet the analyst community has responded by raising targets — a widening gap between Street conviction and market price that defines this week's setup.
The target-raising wave that began last week has continued without pause. Citigroup lifted its target to $1,600 on Tuesday. UBS moved to $1,425 from $1,250 on Monday. The week prior saw JP Morgan go to $1,400 and B of A to $1,334. Every firm that has acted in the past ten days maintained a positive rating. The consensus mean now sits at $1,259 — roughly 9% above the current price, the widest gap between target and market price in recent weeks. That is a meaningful reversal from the July 8 note, which flagged that consensus had effectively caught up to the stock. The stock has since fallen far enough that analysts now lead it again — though Guggenheim's modest target trim to $1,273 is a small dissenting signal in an otherwise uniformly bullish chorus.
The Q2 results released earlier this month give the bulls a foundation. Revenue of $20.7 billion beat consensus by roughly $200 million, driven by the cardiometabolic and oncology franchises. The bear case centres on pricing pressure for Tirzepatide, slower-than-expected uptake of Foundayo, and the challenge that a PE multiple around 27x leaves little tolerance for execution misses. That valuation has drifted down about one turn over the past week as the price has fallen, and EV/EBITDA around 22x has similarly eased. The EPS momentum factor scores remain constructive — 30-day momentum ranks in the 63rd percentile, 90-day in the 76th — while the short score of 30 continues to flag low short pressure.
Positioning data reinforces that the pullback is being driven by buyers stepping back, not shorts pressing in. Short interest has edged down to 0.95% of the free float — marginally above the 0.93% reading from last week's report but still near multi-month lows. Borrow remains almost free at 0.42% cost-to-borrow, itself 9% lower than a week ago. Availability is essentially unconstrained. Options positioning is the more interesting data point: the put/call ratio has climbed to 1.15 from 1.05 last week, edging back toward its 20-day average of 1.13. That is not a defensive extreme, but the directional move — from well below average to near-average in a single week — reflects investors reaching for modest protection as the stock retreats. The z-score of 0.38 keeps it well within normal range.
The peer picture offers context. MRK fell 6.3% on the week, JNJ dropped 5%. Broad pharma weakness is clearly doing part of the work, as it was last week when the US-Iran macro shock pressured high-multiple names. Lilly's 6.7% decline is slightly worse than its closest peers on a weekly basis, consistent with its higher valuation carrying greater sensitivity to risk-off moves. Macro pressure and earnings proximity are a familiar combination for a stock that jumped more than 13% the day after its April 30 results.
With August 5 now three weeks out, the question for the next report is whether the analyst target premium — currently sitting at a fresh high — acts as a gravitational pull back toward $1,260, or whether pre-earnings caution keeps the stock under pressure as options buyers gradually build more defensive positioning.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
